Gastrinoma;Gastrinoma

Endocrinologia y Nutricion

Volumn 54, Issue SUPPL. 1, 2007, Pages 21-30

  Sanabria, Concha ^a   Pérez Ferre, Natalia ^a   Lecumberri, Edurne ^a   De Miguel, Paz ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Gastrinoma; Octreotide; Somatostatin analogs; Zollinger Ellison syndrome

Indexed keywords

ANGIOPEPTIN; CYANOCOBALAMIN; ESOMEPRAZOLE; LANSOPRAZOLE; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PASIREOTIDE; PEGINTERFERON ALPHA2A; PROTON PUMP INHIBITOR; RABEPRAZOLE; RADIOISOTOPE; RECOMBINANT INTERFERON; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

ALGORITHM; CLINICAL FEATURE; CLINICAL PROTOCOL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE MARKER; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; HISTOPATHOLOGY; HUMAN; HYPERGASTRINEMIA; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; SCINTIGRAPHY; SENSITIVITY ANALYSIS; STOMACH ACID; SURVIVAL; TREATMENT INDICATION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

EID: 34547659745     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(07)71515-2     Document Type: Article

References (98)

1. Zollinger RM, Ellison EH. Primary peptic ulceration of the jejunum associated with islet cell tumours of the pancreas. Ann Surg. 1955;42:709.
2. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology. 2004;80:394424.
3. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: reaprasial and evaluation of 260 registred cases. Ann Surg. 1964;160:512.
4. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine. 2000;79:379-411.
5. th ed. p.1377-91.
6. Tartaglia A, Bianchini S, Vezzadini P. Biochemical diagnosis of gastroenteropancreatic endocrine tumors. Minerva Med. 2003;941-7.
7. Roy PK, Venzon DJ, Feigenbaum KM, Koviack PD. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine. 2001;80:222.
8. Kaltas GA, Besser GM, Grossman AB. The diagnosis and medical manegement of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511.
9. Kwekkeboom D, Krenning EP, De Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-13.
10. Lamberts SW, Van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1994;334:246-54.
11. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol. 1999;13:82-90.
12. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-4.
13. Krenning EP, De Jong M, Kooij PP, Breeman WA, Bakker WH, De Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10 Suppl 2:S23-9.
14. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-8.
15. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36:623-7.
16. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide. J Nucl Med. 2000;42:1134-8.
17. Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 1993;20:431-3.
18. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S47-50.
19. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med. 1993;20:716-31.
20. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion. 2000;62 Suppl 1:84-91.
21. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251-61.
22. Krenning EP, Kwekkeboom DJ, De Jong M, Visser TJ, Reubi JC, Bakker WH, et al. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. Semin Oncol. 1994;21:6-14.
23. Krenning EP, Kwekkeboom DJ, Oei HY, De Jong RJ, Dop FJ, Reubi JC, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci. 1994;733:416-24.
24. Krenning EP, Kwekkeboom DJ, Oei Y, Reubi JC, Lamberts SW. Octreotide agent shows peptide imaging potential. Diagn Imaging (San Franc). 1993;15:88-91, 117.
25. Krenning EP, Kwekkeboom DJ, Reubi JC, Van Hagen PM, Van Eijck CH, Oei HY, et al. 111In-octreotide scintigraphy in oncology. Digestion. 1993;54 Suppl 1:84-7.
26. Chiti A, Fanti S, Savelli G, Romeo A, Bellañova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25:1396-403.
27. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26-34.
28. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serraño J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539-53.
29. Hoefnagel CA, Schornagel J, Valdes Olmos RA. [131I] metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med. 1991;35:308-12.
30. Kaltsas GA, Putignaño P, Mukherjee JJ, Satta MA, Lowe DG, Britton KE, et al. Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide. Clin Endocrinol (Oxf). 1998;49:685-9.
31. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895-902.
32. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12 Suppl 2:S31-6.
33. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-21.
34. Bombardieri E, Maccauro M, Castellani MR, Chiti A, Procopio G, Bajetta E, et al. Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure? Minerva Endocrinol. 2001;26:197-213.
35. De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463-9.
36. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci. 2002;970:159-69.
37. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman P. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170:1369-73.
38. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
39. Zimmer T, Ziegler K, Baden M, Fett U, Hamm B, Riecken EO, et al. Localization of neuroendocrine tumors of the upper gastrointestinal tract. Gut. 1994;35:471.
40. Dromain C, De Baere T, Lumbroso J, Caillet M, Laplanche A, Boige V. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography and magnetic resonance imaging. J Clin Oncol. 2005;23:70.
41. Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214:483-90.
42. London JF, Shawker TH, Doppman JL, Frucht HH, Vinayek R, Stark HA, et al. Zollinger-Ellison syndrome: prospective assessment of abdominal US in the localization of gastrinomas. Radiology. 1991;178:763-7.
43. King CM, Reznek RH, Dacie JE, Wass JA. Imaging islet cell tumours. Clin Radiol. 1994;49:295-303.
44. Jensen RT. Gastrointestinal endocrine tumours. Gastrinoma. Baillieres Clin Gastroenterol. 1996;10:603-43.
45. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg. 1996;20:203-7.
46. Arnold R, Frank M. Gastrointestinal endocrine tumours: medical management. Baillieres Clin Gastroenterol. 1996;10:737-59.
47. Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg. 1993;17:504-10.
48. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7:597-610.
49. Goldfinger SD. Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma). Up To Date. 2006.
50. Brazeau P, Vale W, Burgus R, et al. Hypothalamic peptide that inhibit the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-9.
51. Öberg K, Kvols M, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the manegement of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:996-73.
52. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Digestion. 1999;60 Suppl 2:9-14.
53. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10 Suppl 2:S31-8.
54. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402-8.
55. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276-81.
56. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127-30.
57. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol. 2001;12 Suppl 2:S105-9.
58. Lamberts SW, Van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol. 2002;146:701-5.
59. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-16.
60. Oberg K, Eriksson B, Janson ET. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci. 1994;733:471-8.
61. Oberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10 Suppl 2:S3-8.
62. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62 Suppl 1:92-7.
63. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur J Haematol. 1997;59:129-35.
64. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol. 1993;32:203-8.
65. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and ?-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381-7.
66. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon ?, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-96.
67. Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S111-4.
68. Öberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol. 1998;10:58-65.
69. Kaltsas G, Mukherjee JJ, Plowman PN, Grossman AB. The role of the chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol (Oxf). 2001;55:575-87.
70. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med. 2002;44:3-12.
71. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion. 2000;62 Suppl 1:73-8.
72. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-22.
73. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer. 1990;65:1883-90.
74. Oberg K. Treatment of neuroendocrine tumors. Cancer Treat Rev. 1994;20:331-5.
75. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 1993;22:941-52.
76. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-23.
77. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol.1984;2:1255-9.
78. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189-94.
79. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med. 1973;79:108-18.
80. Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB Jr, Peterson R, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1914-8.
81. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372-8.
82. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998;21:36-8.
83. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf). 2002;57:169-83.
84. Ahlman H, Wangberg B, Jansson S, Friman S, Olausson M, Tylen U, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion. 2000;62 Suppl 1:59-68.
85. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
86. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45.
87. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62 Suppl 1:79-83.
88. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumours with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25:272-8.
89. Krening EP, De Jong M, Kooij PP, Breeman WA, Baker WH, De Herder WW, et al. Radiolabelled somatostatin analogues for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10 Suppl 2:S23-9.
90. Kwekkeboom D, Krenning EP, De Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-31.
91. Fjalling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1- octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519-21.
92. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44:1-6.
93. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-40.
94. Brandi ML, Gagel RF, Angeli A, Beck-Pecoz P, Bordi C, Conte-Dekvix B, et al. CONSENSUS: guidelines for diagnosis and therapy of MEN type 1 and Type 2. J Clin Endocrinol Metabol. 2001;12:5658-71.
95. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, Goede A, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology. 2004;80:394-424.
96. Shomanesh H, Gribil F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002;94:331-43.
97. Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A, et al. Octreotide in control of multiple liver metastases from gastrinoma. J Gastroenterol. 2003;38:905-8.
98. Tomassetti P, Campana D, Piscitelli L, Mazzotta E, Brocchi E, Pezzilli R, et al. Treatment of Zollinger-Ellison syndrome. World J Gastroenterol. 2005;11:5423-32.